Scarica l'app Stockscreener
1.415
3.63%
0.045
Precedente Chiudi:
$1.37
Aprire:
$1.36
Volume 24 ore:
1.44M
Relative Volume:
0.35
Capitalizzazione di mercato:
$374.17M
Reddito:
$194.75M
Utile/perdita netta:
$-51.26M
Rapporto P/E:
-5.0536
EPS:
-0.28
Flusso di cassa netto:
$-23.38M
1 W Prestazione:
+5.95%
1M Prestazione:
-14.48%
6M Prestazione:
-63.12%
1 anno Prestazione:
-40.60%
Intervallo 1D:
$1.36
$1.42
Intervallo di 1 settimana:
$1.30
$1.42
Portata 52W:
$1.30
$4.0787
Akebia Therapeutics Inc Stock (AKBA) Company Profile
Nome
Akebia Therapeutics Inc
Settore
Telefono
617-871-2098
Indirizzo
245 FIRST STREET, CAMBRIDGE, MA
Confronta AKBA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AKBA
Akebia Therapeutics Inc
|
1.41 | 363.55M | 194.75M | -51.26M | -23.38M | -0.28 |
|
ZTS
Zoetis Inc
|
124.03 | 55.12B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.97 | 50.80B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.27 | 45.60B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.64 | 36.04B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
470.62 | 20.23B | 3.08B | 1.24B | 1.07B | 25.61 |
Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-04 | Ripresa | H.C. Wainwright | Buy |
| 2025-04-28 | Iniziato | Leerink Partners | Outperform |
| 2025-04-01 | Iniziato | Jefferies | Buy |
| 2023-11-29 | Ripresa | BTIG Research | Buy |
| 2023-08-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-05-31 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-03-31 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-03-31 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-31 | Downgrade | Needham | Buy → Hold |
| 2022-03-31 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-03-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-01-29 | Downgrade | JP Morgan | Neutral → Underweight |
| 2019-11-14 | Reiterato | Needham | Buy |
| 2019-08-06 | Reiterato | H.C. Wainwright | Buy |
| 2019-07-11 | Reiterato | H.C. Wainwright | Buy |
| 2019-05-02 | Iniziato | JP Morgan | Overweight |
| 2019-03-20 | Iniziato | Citigroup | Neutral |
| 2018-09-07 | Ripresa | Morgan Stanley | Equal-Weight |
| 2018-08-10 | Reiterato | Needham | Buy |
| 2018-06-06 | Reiterato | H.C. Wainwright | Buy |
| 2017-12-19 | Iniziato | Piper Jaffray | Overweight |
| 2017-12-07 | Iniziato | BTIG Research | Buy |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2017-07-10 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-27 | Reiterato | Needham | Buy |
| 2016-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2016-12-20 | Reiterato | JMP Securities | Mkt Outperform |
| 2016-11-15 | Iniziato | Aegis Capital | Buy |
| 2016-09-29 | Iniziato | Brean Capital | Buy |
| 2016-03-16 | Reiterato | Needham | Buy |
| 2016-01-21 | Iniziato | Credit Suisse | Neutral |
Mostra tutto
Akebia Therapeutics Inc Borsa (AKBA) Ultime notizie
Highs Report: Can Akebia Therapeutics Inc deliver alpha2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
In the wake of Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) latest US$48m market cap drop, institutional owners may be forced to take severe actions - simplywall.st
Exit Recap: Can Akebia Therapeutics Inc benefit from deglobalizationJuly 2025 Action & Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Analyst Calls: What’s the beta of Akebia Therapeutics Inc. stock2025 Retail Activity & Daily Volume Surge Signals - baoquankhu1.vn
Akebia Post-Selloff: Revenue Dynamics And Upcoming Catalysts (NASDAQ:AKBA) - Seeking Alpha
Akebia Therapeutics announces corporate updates and 2026 pipeline outlook - MSN
Akebia reports first patient dosed in rare kidney disease trial By Investing.com - Investing.com Nigeria
Akebia Therapeutics (NASDAQ:AKBA) Shares Cross Below Fifty Day Moving AverageHere's Why - MarketBeat
Akebia (AKBA) Updates on Vafseo and Rare Kidney Disease Pipeline - GuruFocus
Akebia Therapeutics (AKBA) Reports Growth in Vafseo Prescriptions - GuruFocus
Akebia Therapeutics Outlines 2026 Vafseo Strategy and Pipeline - TipRanks
Akebia reports first patient dosed in rare kidney disease trial - Investing.com
Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook - The Manila Times
How Akebia Therapeutics Inc. stock performs in weak economyJuly 2025 Closing Moves & AI Powered Buy and Sell Recommendations - Улправда
Akebia Therapeutics, Inc. (AKBA) Stock Analysis: Unveiling a Potential 262% Upside for Healthcare Investors - DirectorsTalk Interviews
What insider trading reveals about Akebia Therapeutics Inc. stockModel Comparison & HOKA buying tips before checkout - Улправда
How supply chain issues affect Akebia Therapeutics Inc. stock2025 Analyst Calls & Weekly Top Performers Watchlists - Улправда
Q32 Bio Shares Soar After Offloading Phase 2 Complement Drug to Akebia - MSN
Is Akebia Therapeutics Inc. stock affected by interest rate hikesMarket Sentiment Summary & Stock Timing and Entry Methods - ulpravda.ru
How Akebia Therapeutics Inc. (AX9) stock trades pre earningsCPI Data & Trade Opportunity Analysis Reports - Улправда
Can Akebia Therapeutics Inc. stock outperform in 2025 bull market2025 Year in Review & Long-Term Safe Return Strategies - Улправда
Akebia announces first patient dosed in Phase 2 trial of praliciguat - Yahoo Finance
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug - Investing.com Nigeria
Key facts: Akebia starts Phase 2 trial for Praliciguat; grants stock options - TradingView — Track All Markets
Akebia Therapeutics announces first patient dosed in phase 2 clinical trial of praliciguat - marketscreener.com
Akebia Therapeutics begins phase 2 trial for rare kidney disease drug By Investing.com - Investing.com South Africa
Akebia Therapeutics Announces First Patient Dosed in Phase - GlobeNewswire
New pill tested for rare kidney disease with no approved treatments - Stock Titan
Akebia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Akebia Therapeutics expands portfolio beyond anemia with new rare kidney disease pipeline centered on AKB-097 and praliciguat - MSN
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
U.S. Renal Care Enrolled First Patients in the VOICE Collaborative Clinical Trial of Vafseo® (vadadustat) for CKD Patients on Dialysis - Quantisnow
Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat - Finviz
Dow Update: Can Akebia Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 Reactions & Accurate Intraday Trade Tips - moha.gov.vn
Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN
Akebia Therapeutics Earnings Notes - Trefis
Why Akebia Therapeutics Inc. (AX9) stock gets analyst attention2025 Performance Recap & Stepwise Trade Signal Implementation - Улправда
Is Akebia Therapeutics Inc. stock a buy for dividend growthPrice Action Analysis & Swing Trade Smarter With Data Insights - Bollywood Helpline
Volume Report: Can Akebia Therapeutics Inc. stock outperform in 2025 bull market - Улправда
How Low Can Akebia Therapeutics Stock Really Go? - Trefis
Why Akebia Therapeutics Inc. stock is a must watch in 2025July 2025 Momentum & Fast Moving Market Watchlists - Улправда
Is Akebia Therapeutics Inc. stock safe for conservative investorsJuly 2025 Price Swings & Stepwise Swing Trade Plans - Улправда
Can Akebia Therapeutics Inc. stock deliver sustainable ROEEarnings Overview Report & Expert Curated Trade Setup Alerts - Улправда
Akebia Therapeutics Inc Azioni (AKBA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.40%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):